<DOC>
	<DOCNO>NCT03053427</DOCNO>
	<brief_summary>The objective study assess efficacy once-daily oral administration Gabapentin enacarbil versus placebo , base change International Restless Legs Syndrome Rating Scale ( IRLS ) score subject moderate-to-severe primary Restless Legs Syndrome . This study also assess safety Gabapentin enacarbil .</brief_summary>
	<brief_title>A Study Oral Dosing Gabapentin Enacarbil Japanese Restless Legs Syndrome Patients</brief_title>
	<detailed_description>Subjects receive 14 week Gabapentin enacarbil placebo .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Subject Restless Legs Syndrome ( RLS ) , base International Restless Legs Syndrome Study Group ( IRLSSG ) Diagnostic Criteria . Subject report history RLS symptoms least 15 day month prior first dosing ; treatment , frequency symptom start treatment . Subject International Restless Legs Syndrome Rating Scale ( IRLS ) score ≥ 15 . Subject discontinue dopamine agonist , and/or gabapentin least 1 week prior first dose . Subject discontinued treatment RLS least 2 week prior first dose . Female subject must either : Be nonchildbearing potential : Postmenopausal ( define least 1 year without menses ) prior Screening , document surgically sterile Or , childbearing potential : Agree try become pregnant study 28 day final study drug administration And negative urine pregnancy test Screening And , heterosexually active , agree consistently use two form highly effective birth control start Screening throughout study period 28 day final study drug administration . Female subject must agree breastfeed start Screening throughout study period , 28 day final study drug administration . Female subject must donate ovum start Screening throughout study period , 28 day final study drug administration . Subject agree participate another interventional study treatment . Subject Body Mass Index ≥ 18.5 &lt; 30 . Subject estimate creatinine clearance ≥ 60 mL/min . Subject sleep disorder may significantly affect assessment RLS . Subject history RLS symptom augmentation endofdose rebound previous dopamine agonist treatment . Subject neurologic disease movement disorder . Subject poorly control diabetes , iron deficiency anemia , currently take sedative/hypnotic . Subject history sucide attempt within 6 month prior inform consent . Subject high level Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) . Subject currently suffer moderate severe depression . Subject history alcohol dependence drug abuse , subject alcohol drug abuse dependence last 1 year . Subject shift worker , professional driver , operator dangerous machinery . Subject clinically significant unstable medical condition . Subject history hypersensitivity reaction gabapentin . Subject previously take pregabalin , gabapentin enacarbil , study drug Gabapentin enacarbil . Subject participate clinical study another investigational drug medical device postmarketing clinical study within 12 week ( 84 day ) prior first dosing , currently participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Gabapentin enacarbil</keyword>
</DOC>